NC
OMED

Nexthera Capital’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Nexthera Capital’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-634,715
Closed -$1.35M – 60
2018
Q3 		$1.35M Buy
+634,715
New +$1.52M 0.26% 41

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Nexthera Capital's OMED Position: Q4 2018 in Review

Nexthera Capital sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 634,715 shares — an estimated $1.35M sold.

Nexthera Capital first reported a position in OMED in Q3 2018 and held it in 1 quarter. The position peaked at $1.35M in Q3 2018. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Nexthera Capital reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Nexthera Capital sold 634,715 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $1.35M.
  • Nexthera Capital first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Nexthera Capital's OncoMed Pharmaceuticals, Inc. position peaked at $1.35M in Q3 2018.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.